mRNA Synthesis and Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product

mRNA Synthesis and Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product

The mRNA Synthesis and Manufacturing Market is valued at USD 1.06 billion in 2024. Ribonucleic acid (RNA) is a ubiquitous molecule found in all the living cells, which is responsible for translating genetic information into proteins which is important for various cellular processes. RNA comes in different forms, including messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA), with mRNA emerging as a prominent therapeutic modality in modern healthcare. mRNA is a single-stranded molecule that carries genetic information from DNA to produce proteins. This genetic code on mRNA is translated into amino acids, which are then processed into functional proteins. Since the onset of the COVID-19 pandemic, mRNA vaccine and therapeutic manufacturing have garnered considerable attention, emerging as a next-generation drug class not only for COVID-19 but also for various other conditions like oncological disorders, infectious diseases, and genetic disorders.

However, producing mRNA therapeutics and vaccines is a complex and expensive process which demands specialized expertise and capabilities. Consequently, developers of mRNA therapeutics and vaccines are actively exploring solutions to overcome these challenges. Outsourcing has emerged as an attractive option for mRNA developers, offering potential solutions to these hurdles. Looking ahead, with the increasing prevalence of chronic diseases, growing demand for gene therapy, maturation of RNA-based therapies in clinical and commercial stages, and advancements in technology, we anticipate robust growth in the mRNA synthesis and manufacturing market.



Key Market Segments

Type of Product

Drug Substance (APIs)

Drug Product (FDFs)

Application Area

mRNA-based Vaccines

mRNA-based Therapeutics

Therapeutic Area

Infectious Diseases

Oncological Disorders

Other Diseases

Key Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

Research Coverage:

An overview of structure and the historical evolution of mRNA vaccines. A comprehensive discussion pertaining the information on the synthetic mRNA production, both chemically and in vitro, and its applications across various therapeutic area. Further, it features the challenges associated with the synthesis and manufacturing processes of mRNA are outlined as well. Further, the module delves into the commonly outsourced manufacturing operations and their advantages.

A comprehensive evaluation of mRNA custom synthesis service providers, considering several relevant parameters, such as year of establishment, company size (measured by the number of employees), headquarters location (North America, Europe, and Asia Pacific), types of services offered (such as mRNA modification, purification, scale-up, process development, and fill/finish), starting material (plasmid DNA, mRNA sequence, PCR fragments), structural modification (5’ modification, 3’ modification, ribonucleotide base modification, and others), purification methods (chromatography, electrophoresis, desalting/precipitation, and others), application areas (vaccine production, therapeutic production, and others), and scale of operation (preclinical/research, clinical, and commercial). Additionally, the chapter includes information on the length of the mRNA manufactured and the production capacity of the stakeholders.

An in-depth competitiveness analysis of mRNA custom synthesis service providers across key geographical regions. This analysis takes into account the supplier strength, including years of experience and company size, as well as service strength, which encompasses the number and types of services offered, modifications, scale of operation, compliance with Good Manufacturing Practices (GMP), and application areas.

A thorough assessment of mRNA contract manufacturing service providers, considering various pertinent parameters. These parameters include the year of establishment, company size (measured by the number of employees), headquarters location (North America, Europe, and Asia Pacific), location of manufacturing facilities, types of additional services offered (such as formulation development, analytical testing, process development, mRNA purification, fill / finish, scale-up, regulatory support, and others), type of product manufactured (drug substances (APIs) and drug products (FDFs)), and scale of operation (preclinical/research, clinical, and commercial).

A thorough company competitiveness analysis of mRNA contract manufacturing service providers across key geographical regions, focusing on the supplier strength and service portfolio strength. Supplier strength is assessed based on years of experience and company size, while service portfolio strength considers factors such as the number of facilities, type of products manufactured, variety of services offered, and scale of operation.

A comprehensive evaluation of the current market landscape of mRNA synthesis kits, considering various pertinent parameters. These parameters include kit components (such as enzyme mix, reagents, buffer, etc.), types of enzymes utilized (including capping enzyme and tailing enzyme), enzyme mix variants (such as T7 polymerase, SP6 polymerase, and T3 polymerase), mRNA components modified (cap, base, and tail), number of reactions per kit (ranging from 5 to 50 reactions), yield per reaction (categorized by microgram ranges), reaction run time (classified by duration), and kit price (grouped into price ranges). Furthermore, the chapter provides an extensive analysis of mRNA synthesis kit providers, offering insights into their year of establishment, company size (measured by employee count), headquarters location, and the most active players in terms of the number of mRNA synthesis kits offered.

A detailed analysis of mRNA synthesis kits, focusing on the supplier strength and product attributes. Supplier strength is evaluated based on years of experience and company size, while product strength is assessed based on the number of kit components, types of enzymes included, types of mRNA components modified, yield per reaction, number of reactions per kit, reaction run time, and kit price.

Detailed company profiles of the top mRNA manufacturing companies based on their robust service offerings. Each profile includes a concise company overview, encompassing establishment year, headquarters location, employee count, and notable executives. Additionally, it delves into their mRNA synthesis and manufacturing services, recent advancements, and well-informed future perspectives. Further, the leading service providers in mRNA synthesis and manufacturing, profiles of other noteworthy players have been included, featuring company background and mRNA synthesis and manufacturing service details.

Comprehensive profiles of leading mRNA synthesis kit providers have been curated, selected for their robust product portfolios. Each profile provides a succinct company overview, coupled with details on their mRNA synthesis kits portfolio.

An exhaustive examination of partnerships formed among stakeholders within this industry between 2019 and 2023, taking into account various parameters. These parameters include the year of partnership, nature of partnership, product type, partner type, and identification of the most prolific players based on the quantity of partnerships forged. Furthermore, the analysis offers insights into the regional distribution of the companies engaged in these collaborations.

A comprehensive analysis of over 35 developers of mRNA-based therapeutics and vaccines, identified for potential partnerships with mRNA contract manufacturing service providers. These developers have been carefully shortlisted based on various parameters including the strength of the developer (evaluated through company experience), company size (measured by the number of employees), pipeline robustness (assessed by the quantity of mRNA-based drugs in the pipeline), highest development phase attained, therapeutic focus, route of administration, and the type of candidates under development.

An comprehensive examination of the diverse mRNA-focused initiatives undertaken by major pharmaceutical companies, selected based on their 2023 revenues. This review highlights trends across multiple parameters, including the quantity of initiatives, initiation year, purpose, type, and therapeutic focus of each initiative.

A detailed analysis on the factors influencing the growth of the mRNA synthesis and manufacturing market. This study includes the identification and examination of key drivers propelling market expansion, potential restraints hindering growth, emerging opportunities for market advancement, and existing challenges that may impede progress.

In-depth forecast analysis of the mRNA synthesis and manufacturing market to estimate both the current market size and the future opportunities up to the year 2035. Utilizing multiple parameters such as anticipated adoption trends and rigorous primary validations, we have derived an informed estimate of the market evolution during the forecast period from 2024 to 2035. Furthermore, this module outlines the likely distribution of the current and forecasted opportunities within the mRNA synthesis and manufacturing market. To enhance the robustness of our model and to accommodate future uncertainties, we have developed three forecast scenarios: conservative, base, and optimistic. These scenarios represent different trajectories of industry growth, providing a comprehensive perspective on potential market developments.

Detailed projections have been formulated for the current and future mRNA synthesis and manufacturing market, categorized by type of product, encompassing both drug substances and drug products. These projections offer comprehensive insights into the anticipated growth trajectories, market sizes, and emerging trends for each product type within the mRNA synthesis and manufacturing landscape.

Detailed projections of the current and future mRNA synthesis and manufacturing market across application area, such as mRNA-based vaccines and mRNA-based therapeutics.

Detailed projections of the current and future mRNA synthesis and mRNA manufacturing market across therapeutic area, such as infectious diseases, oncological disorders and other disorders.

Detailed projections of the current and future mRNA synthesis and manufacturing market across key geographies, such as North America, Europe, Asia-Pacific, and Rest of the World.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the mRNA Synthesis and Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

Aldevron

APExBIO

Aurigene Pharmaceutical Services

Biomay

CELLSCRIPT

Curia

eTheRNA

Enzynomics

Eurogentec

Genscript

Jena Bioscience

Merck KGaA

New England Biolabs

Vernal Biosciences

ST Pharm

Thermo Fisher Scientific

TriLink BioTechnologies

WuXi Biologics